Loading organizations...
Neumora Therapeutics develops novel precision medicines for neuropsychiatric and neurodegenerative diseases. The company employs a distinct approach to drug discovery, identifying and targeting specific biological drivers of brain conditions. This precision medicine framework aims to deliver more effective therapies by aligning treatments with defined patient populations, moving beyond conventional broad-spectrum methods.
Founded in late 2019 by leaders including Paul L. Berns and Carol Suh, Neumora emerged from the critical need for improved brain disease treatments. Founders recognized the challenges of heterogeneous conditions and limited existing therapies. Their insight was to pioneer new neuroscience drug development through a precision medicine strategy.
Neumora’s pipeline targets individuals living with various neuropsychiatric and neurodegenerative conditions. The company’s vision centers on redefining neuroscience through discovering, developing, and commercializing novel therapies. Its ultimate goal is to provide improved patient outcomes, addressing substantial unmet medical needs.
Neumora Therapeutics has raised $510.0M across 2 funding rounds.
Neumora Therapeutics has raised $510.0M in total across 2 funding rounds.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric disorders like major depressive disorder and neurodegenerative conditions such as Alzheimer's and Parkinson's.[1][2][3] It builds a data-driven neuroscience platform that integrates data science to identify patient subtypes via Data Biopsy Signatures™ and Precision Phenotypes™, enabling targeted therapies like navacaprant (NMRA-140), a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder, and NMRA-511 in Phase 1 for agitation in Alzheimer's dementia.[2][3][4] The company serves patients with unmet needs in CNS diseases, solving the problem of brain disease heterogeneity through novel mechanisms and best-in-class pharmacology, with strong growth momentum evidenced by its 2021 initial investment, NASDAQ listing (NMRA), and advancing pipeline including preclinical programs for schizophrenia and ALS.[2][3][4]
Headquartered in Watertown, Massachusetts, and founded in 2019, Neumora addresses a global brain disease crisis by redefining neuroscience R&D, much like precision oncology advancements.[3][5]
Neumora Therapeutics was incorporated in November 2019 as RBNC Therapeutics, Inc., and renamed in October 2021, founded by Paul L. Berns (current Chairman & CEO), Carol Suh, and Mike Poole.[2][4] The founders drew on expertise in neuroscience, data science, and biotech to launch a precision medicine approach amid stalled progress in brain disease treatments.[3][5] Early traction came from integrating multimodal data to pinpoint patient subtypes, attracting investment like F-Prime Capital's 2021 funding, and rapidly advancing programs like navacaprant into Phase 3 trials.[2][3][4] Pivotal moments include building a robust advisory board with experts like Edward M. Scolnick and assembling a leadership team including independent directors with deep pharma experience.[2]
Neumora rides the precision medicine wave in neuroscience, applying oncology-inspired data integration to tackle brain diseases—a market plagued by 90%+ clinical failure rates due to patient heterogeneity.[3][5] Timing is ideal amid advancements in multimodal data (genomics, imaging, biomarkers) and AI-driven phenotyping, fueled by aging populations driving demand for Alzheimer's, depression, and Parkinson's therapies.[1][2] Favorable forces include regulatory pushes for CNS innovation and biotech funding resurgence post-2021 lows. Neumora influences the ecosystem by pioneering data platforms that could standardize subtype identification, enabling collaborations and accelerating rivals' R&D.[3][4]
Neumora's Phase 3 readouts for navacaprant in 2026 could catalyze approvals and partnerships, expanding into bipolar disorder (Phase 2) and dementia agitation.[2][4] Trends like AI-biomarker integration and CNS gene therapies will shape its path, potentially scaling preclinical assets to clinic amid a $100B+ brain disease market. Its influence may evolve from pipeline pioneer to platform licensor, redefining biotech's fight against the brain crisis—delivering the targeted medicines patients deserve, as promised from day one.[3][5]
Neumora Therapeutics has raised $510.0M in total across 2 funding rounds.
Neumora Therapeutics's investors include B Capital Group, Mubadala, Rajan Anandan, Krishna Mehra, Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen Ventures, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Alaa Halawa.
Neumora Therapeutics has raised $510.0M across 2 funding rounds. Most recently, it raised $110.0M Series B in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2022 | $110M Series B | — | B Capital Group, Mubadala, Rajan Anandan, Krishna Mehra, ABU Dhabi Growth Fund, Altitude Life Science Ventures, Amgen Ventures, ARCH Venture Partners, Exor Ventures, F Prime Capital, Invus, Alaa Halawa, Newpath Partners, Polaris Partners | Announced |
| Oct 1, 2021 | $400M Series A | ARCH Venture Partners | Deerfield Management, Flagship Ventures, F Prime Capital, Samsung Ventures, T1D Fund, Alexandria Venture Investments, Altitude Life Science Ventures, Catalio Capital, Stacie Weninger, Invus, Logos Capital, Mubadala Capital, Newpath Partners, Polaris Partners, Re.Mind Capital, Softbank, Surveyor Capital, Waycross Ventures | Announced |